亚虹医药(688176.SH)在ECC发布APL-1401Ⅰb期临床试验相关数据

Core Viewpoint - Aihong Pharmaceutical (688176.SH) announced that the results of its phase Ib clinical trial for APL-1401, aimed at treating moderate to severe active ulcerative colitis, were selected for presentation at the 19th European Colorectal Congress (ECC) in the form of a poster [1] Group 1 - APL-1401 is an innovative oral drug discovered through the company's independent research, featuring a novel mechanism of action for treating autoimmune diseases [1] - APL-1401 acts as a potent and selective dopamine β-hydroxylase (DBH) inhibitor, which blocks the only catalytic enzyme for the synthesis of norepinephrine (NE) from dopamine (DA) [1] - The inhibition of DBH leads to an increase in DA levels and a decrease in NE levels, thereby restoring intestinal immune homeostasis [1]